According to the company, the new module supplements existing search options in addition to proprietary histopathology, in vivo pharmacology, tumor growth, and molecular pathology data.
With the update, users will be able to search and interact with dose response curves and IC50 data for more than 290 cell lines.
Qian Shi, Ph.D., vice president of cancer pharmacology and in vitro cancer biology at CrownBio said, “Getting instant access to in vitro pharmacology data linked to in vivo data from the corresponding cell line derived xenograft in one comprehensive and easy-to-browse platform means clients will be able to plan their studies with an end-to-end solution in mind.”